Introduction {#Sec1}
============

There are more than 1.3 billion people in China, which make almost 1/6 of world's population, and largely contribute to a global patients' community. During the 2015 in China, there were more than 6.6 million deaths from non-communicable diseases (NCDs), which was the highest rate around the world \[[@CR1]\]. Over the past decade, diseases such as diabetes mellitus (DM), coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), and hypertension have become the most common chronic diseases. China is the home to largest number of DM patients worldwide. It is estimated that there are currently 109.6 million adults living with DM, while in 2015 there were 1.3 million deaths caused by DM \[[@CR2]\]. Furthermore, the economic burden of DM is substantial. In China, healthcare expenditures related to diabetes were 51 billion dollars in 2015, and they are expected to increase to 72 billion dollars by 2040 \[[@CR2]\]. According to the fifth national health services survey in China, currently there are approximately 10.2 thousand CHD patients per million people \[[@CR3]\], which is an increase of 34.5% in number of patients from 2008 \[[@CR4]\]. COPD is characterized by chronic airflow limitation. It is a progressive lung disease and a leading cause of global death \[[@CR5]\]. In China, the prevalence of COPD varies from 5 to 13% \[[@CR6]\]. More than one billion people worldwide are diagnosed with hypertension, which is a NCD that causes stroke, heart disease, and kidney failure \[[@CR7]\]. The hypertension prevalence rate is 14.3% among the population aged over 35 years or older in China \[[@CR3]\]. The burden of disease among the aging population has become more serious than ever. In China, there are more than 0.23 billion people aged over 60, which accounted for 16.7% of the total population in 2016 \[[@CR8]\]. The number of elderly people has increased by 29.5% since 2010 \[[@CR9]\].

Following the shift from biomedicine model to the bio-psycho-social medical model \[[@CR10]\], people have gained a deeper health awareness. Nowadays, the health measurements evaluate the life expectancy, as well as the quality of life (QoL). WHO has defined QoL as "the individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals" \[[@CR11]\]. The concept of health-related quality of life (HRQoL) can be interpreted as an indicator of individual's well-being, and as effective pointer of potential health gains that can be brought on by various interventions \[[@CR12]\]. The plan for "Healthy China 2030" was approved by the Political Bureau of the Communist Party of China Central Committee in 2016. Health promotion is an important part of national development strategy, and will remain so for at least next 15 years. Meanwhile, the healthcare reform in China is ever more comprehensive, thus improving the HRQoL in the whole population is one of its most important goals.

Patients' health-related preferences have an important role for exploring their disease progression and survival, while health utility can be used to represent individual's preference for a particular health state, which is widely used in health-related research and cost-utility analysis \[[@CR13]\]. There are several health utility generic instruments, which mainly include the EuroQol 5-Dimensions (EQ-5D) \[[@CR14]\], Health Utilities Index (HUI) \[[@CR15]\], and Short Form-6 Dimensions (SF-6D) \[[@CR16]\] questionnaires. The three-level version EQ-5D questionnaire (EQ-5D-3L) was introduced by EuroQol Group in 1990. EQ-5D-3L has been recommended by both the UK National Institute of Health and Care Excellence (NICE) and China Guidelines for Pharmacoeconomic Evaluations (2011 edition) as a preferred outcome measure tool \[[@CR17], [@CR18]\].

EQ-5D-3L comprises five dimensions, including "Mobility," "Self-Care," "Usual Activities," "Pain/Discomfort," and "Anxiety/Depression." The questionnaire is divided in dimensions, and each dimension has three levels: "have no problems/be not," "have some/moderate problems," "have extremely problems/unable to." Therefore, 3L questionnaire can be used to define 243 kinds of different health states \[[@CR19]\]. Based on a value set, we can convert EQ-5D states to a single summary index, namely health utility, which can be used to calculate the Quality-adjusted life years (QALYs). The estimation of EQ-5D-3L value set is based on local people's health preference and is affected by culture, social environment, as well as economic development. Thus, it is necessary to derive country-specific value set for EQ-5D health states. Since 1997, EQ-5D-3L value sets have been estimated by more than 20 countries (China, UK, USA, Korea, Japan, etc.). The questionnaire is currently translated into more than 170 languages, and is widely applied with good reliability and validity in both disease population (diabetes mellitus, hypertension, coronary heart disease, chronic obstructive pneumonia disease, etc.) and general population \[[@CR20]--[@CR23]\].

Due to the rising burden of diseases, it is necessary to pay more attention to HRQoL \[[@CR24]\]. HRQoL can reveal the comprehensive survival state of a patient, and thus can provide more evidence for decision-makers, especially for chronic non-communicable diseases (CNCDs). In recent years, 3L questionnaire has been widely used in Chinese population with CNCDs to measure HRQoL. However, there is a lack of systematic reviews of these studies. The objective of the present review was to identify the kind of CNCD in China that EQ-5D-3L is mostly used for, as well as the variation of health utilities in different studies involving a specific CNCD.

Methods {#Sec2}
=======

Search strategy and selection criteria {#Sec3}
--------------------------------------

We performed a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR25]\]. All relevant studies that reported HRQoL evaluated by EQ-5D-3L questionnaire in Chinese patients with CNCDs were searched in PubMed, Embase, Web of Science, Cochrane Library, VIP, WanFang Data, and CNKI databases up to April 12, 2018. Search terms included "quality of life," "QoL," "HRQoL," "EQ-5D," "EuroQol," "five dimension," "China," "Chinese," "Randomized Controlled Trial," "RCT," "diseases," and "chronic non-communicable," and they were combined using Boolean logic (details in Appendix Table [3](#Tab3){ref-type="table"}). Expert consultation and hand-searching of reference lists from retrieved studies were employed to identify additional references. VIP, WanFang Data, and CNKI are the most commonly used Chinese databases, which covers more than 95% of Chinese literatures, including journal articles, doctoral dissertations, masters' theses, conference papers, reference works, newspapers, patents, and laws.

Following the inclusion criteria, all the studies were cross-sectional researches in Chinese population with CNCDs that were conducted in China, that reported EQ-5D-3L scores about a specific CNCDs with or without comorbidity by applying a value set, and that were full-text available. In this review, CNCDs are defined as "Diseases or conditions that occur in, or are known to affect, individuals over an extensive period of time and for which there are no known causative agents that are transmitted from one affected individual to another." \[[@CR26]\], such as cancer, DM, and COPD. We also included studies where health utility was generated from different country's value set in the same sample. Languages were restricted to English and Chinese. We excluded any study if it was a review, or an abstract that used general population, communicable disease population, non-Chinese population, or Chinese subjects who did not live in China; that was longitudinal survey, intervention effect evaluation; where the only multiple diseases synthetic utility value was reported or there was no utility; and that was unrelated to HRQoL.

Data collection and quality assessment {#Sec4}
--------------------------------------

Preliminary literature screening was performed by two authors independently based on the titles and abstracts. After title/abstract review, full-text articles were reviewed by two investigators to evaluate eligibility of studies for inclusion and to check the bibliography. Two researchers independently conducted data extraction from all included articles using a pre-formulated sheet. Publication details, data sources, sample size (gender), type of disease, mean age, comorbidities, EQ-5D health utilities, EQ-VAS scores, five-dimension results, full health ratio, and value set information were extracted. Disagreement was solved by a further discussion between reviewers. To extract more information, all the results were pooled into a customized sheet when different articles reported HRQoL from the same dataset.

We appraised methodological quality of each study using a 11-item cross-sectional study assessment checklist introduced by Agency for Health Research and Quality (AHRQ) \[[@CR27]\]. Each item was assigned one response option from three alternative choices, "Yes/No/Unclear," based on study description. "Yes" for any item equaled one point, while "No" or "Unclear" equaled zero points. AHRQ defined the quality level of each article, and was obtained by adding all the item scores. A total of 0--3 points meant low quality, 4--7 points moderate quality, and over 7 points signified high quality.

Statistical analysis {#Sec5}
--------------------

The variations of mean utility values described in all studies were reported. Besides that, descriptive analysis of EQ-VAS score ranges and response for each EQ-5D dimension were undertook. We conducted all calculations using Microsoft Excel 2013.

Results {#Sec6}
=======

A total of 5027 English-language articles and 618 Chinese-language articles were identified via seven databases, while six additional studies were included after expert consultation and manual review. After checking for duplicates, we screened 3227 papers to assess for eligibility. Among these, 38 articles met the inclusion criteria \[[@CR28]--[@CR65]\] (Fig. [1](#Fig1){ref-type="fig"}). In total, 18 English-language articles and 20 Chinese-language articles were included in the review analysis. All the included cross-sectional studies were conducted between October 2006 and December 2017 (Table [1](#Tab1){ref-type="table"}). Besides three studies that included only male patients \[[@CR60], [@CR63], [@CR65]\], all the other studies included both male and female patients. The AHRQ checklist score ranged from 4 to 10 points, median score was 7 points, while mode was 7 (details in Appendix Table [4](#Tab4){ref-type="table"}). There was no study of a low quality, while 29 studies were of median quality \[[@CR29]--[@CR31], [@CR33]--[@CR37], [@CR39]--[@CR42], [@CR45]--[@CR52], [@CR54], [@CR55], [@CR57]--[@CR59], [@CR61], [@CR62], [@CR64], [@CR65]\] and 9 were of high quality \[[@CR28], [@CR32], [@CR38], [@CR43], [@CR44], [@CR53], [@CR56], [@CR60], [@CR63]\].

Fig. 1Flow diagram of article selection for inclusion

Table 1Basic characteristics of included studiesSurvey timeLocationPatientsMale (%)DiseaseMean age (SD), yearsAHRQ scoreZhu \[[@CR28]\]201023 provinces965051.0T2DM60.1 (11.7)8Liang \[[@CR29]\]December 2010 to January 2012Beijing city51645.9T2DM62.35Luo et al. \[[@CR30]\]July to October 2008Nanjing city25650.4T2DM63.2 (9.9)6Tang et al. \[[@CR31]\]March 2014 to August 2014Deqing county41555.9T2DM57.2 (16.6)5Han et al. \[[@CR32]\]December 2008 to July 20099 cities708251.1T2DM59.68Chang \[[@CR33]\]October 2006 to June 2007Taiwan49845.8T2DM63.7 (13.8)7Yan et al. \[[@CR34]\]November 2007 to July 2012Hong Kong10,95256.1T2DM Normal ABI58.2 (11.3)7123045.1T2DM Borderline ABI60.4 (14.2)59047.1T2DM PAD68.3 (13.3)Ji et al. \[[@CR35]\]October 2011 to March 2012China99849.6T2DM Normal BMI56.6682249.3T2DM Overweight BMI56.521233.0T2DM Obese BMI53.5Zhu et al. \[[@CR36]\]--Ningbo city319--Diabetes mellitus50.7 (17.31)^a^41383--Hypertension45--COPD41--StrokeCao et al. \[[@CR37]\]August to October 2010Beijing city80227.9Diabetes mellitus57.2 (9.77)^a^5326334.7Hypertension41644.0Stroke193028.0Coronary heart diseaseXiong et al. \[[@CR38]\]August 2007 to January 2010Nanchang city33065.2Coronary heart disease65.4 (10.8)8Wang et al. \[[@CR39]\]August to October 2010Beijing city192829.4Coronary heart disease61.6 (9.2)7Wu et al. \[[@CR40], [@CR41]\]^b^July to December 2011Tianjing and Chengdu city41149.6Chronic stable angina68.1 (11.4)7Wu et al. \[[@CR42]\]March to June 2011Beijing, Guangzhou, Shanghai and Chengdu city67872.9COPD70.4 (10.1)7Chen et al. \[[@CR43]\]September 2010 to May 2011Hong Kong15498.7COPD72.9 (8.1)8Ding et al. \[[@CR44]\]2009China67560.7COPD62.0 (11.4)8Gao et al. \[[@CR45]\]July to October 2012Wuhan city14452.1Epilepsy33.1 (13.0)6Gao et al. \[[@CR46]\]July 2012 to January 2013Wuhan city22053.6Epilepsy31.8 (13.0)5Li et al. \[[@CR47]\]2011 to 2012Hangzhou and Beijing city1006--Hypertension--6He et al. \[[@CR48]\]December 2011 to February 2012Beijing city60638.8Hypertension65.94Wang 2017 \[[@CR49]\]July to September 2017Lian-yungang city212543.2Hypertension59.5 (9.2)7Wang et al. \[[@CR50]\]January to December 2017Dalian city48748.5Hypertension65.6 (6.7)5Zhang et al. \[[@CR51]\]2014Shanghai city41946.3Hypertension--7He et al. \[[@CR52]\]--Baoji city12358.5Cerebral infarction58.6 (13.2)4Wei \[[@CR53]\]November 2012 to March 2013Guangxi Autonomous Region6060.0Cerebral infarction DBP57.5 (10.1)109466.0Cerebral infarction NDBP61.6 (9.8)9967.7Cerebral infarction ADBP66.3 (9.4)Che et al. \[[@CR54]\]December 2012 to June 2013Kunming city9184.6Compensated48 (11.3)619877.8Decompensated49 (11.8)13179.4HCC56 (11.1)10075.0Liver failure44 (12.3)Yu et al. \[[@CR55]\]August to October 2015Beijing city5581.8Compensated50.9 (1.6)66468.8Decompensated52.4 (1.4)4577.8HCC58.4 (1.7)Chen \[[@CR56]\]December 2014 to July 2015Anhui province18868.6Lung cancer26--85^c^8Chen et al. \[[@CR57]\]December 2014 to July 2015Anhui province20978.0Esophagus cancer43--89^c^7Cui \[[@CR58]\]2008Heibei province34063.8cerebral palsy7.8 (2.3)6Gu \[[@CR59]\]July 2008 to January 2009Shanghai city9210.9Rheumatoid arthritis52.5 (12.3)7Jiang \[[@CR60]\]September 2015 to January 2016Shandong province42100.0Sarcopenia68.7 (8.0)9Wang et al. \[[@CR61]\]October 2009 to May 2010Taiwan74259.8Atrial fibrillation70.2 (11.8)7Farooq et al. \[[@CR62]\]June to December 2009Shaanxi province36848.6Kashin beck disease56.9 (10.1)6Zhao et al. \[[@CR63]\]December 2008 to March 2009Kunming city268100.0Chronic prostatitis33.2 (8.0)9Lin et al. \[[@CR64]\]January to May 2008Taipei city31848.1Visual impairment747Sun et al. \[[@CR65]\]June 2011 to February 2012China110100.0Hemophilia30.4 (7.8)6*SD* standard deviation, *AHRQ* agency for health research and quality, *T2DM* type 2 diabetes mellitus, *ABI* ankle-brachial index, *PAD* peripheral arterial disease, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *DBP* dipper blood pressure, *NDBP* non-dipper blood pressure, *ADBP* anti-dipper blood pressure, *HCC* hepatocellular cancer, -- not reported in excluded study^a^Full sample' mean age and SD^b^Same sample applied two different value sets in two articles, respectively^c^Only reported age range

We extracted HRQoL data on 18 kinds of CNCDs based on EQ-5D-3L from the included studies (Table [2](#Tab2){ref-type="table"}). The diseases were diabetes mellitus (DM), hypertension, coronary heart disease (CHD), chronic obstructive pneumonia disease (COPD), epilepsy, cerebral infarction (CI), stroke, chronic liver diseases (CLD), lung cancer (LC), esophagus cancer (EC), cerebral palsy (CP), rheumatoid arthritis (RA), sarcopenia, atrial fibrillation (AF), Kashin Beck disease (KBD), chronic prostatitis (CPT), visual impairment (VD), and hemophilia.

Table 2HRQoL of Chinese disease population based on EQ-5D-3LDiseaseHealth utilityVAS scoresHave some/extremely problems in 5 dimensions (%)Full health (%)Value setAdministrationMean valueSDMean valueSDMobility (%)Self-care (%)Usual activities (%)Pain/discomfort (%)Anxiety/depression (%)Diabetes mellitus Zhu \[[@CR28]\]T2DM0.810.0878.611.46.94.06.119.515.671.0JapanFace-to-face Liang \[[@CR29]\]T2DM0.85--73.9--13.02.57.042.425.6--JapanFace-to-face Luo et al. \[[@CR30]\]T2DM0.790.16----21.57.841.841.836.7--JapanFace-to-face Tang et al. \[[@CR31]\]T2DM0.840.2061.516.521.211.517.338.547.136.5ChinaFace-to-face Han et al. 2013 \[[@CR32]\]T2DM0.870.2171.014.615.58.814.426.826.856.7UKFace-to-face Chang \[[@CR33]\]T2DM0.800.20----------------UKFace-to-face Yan et al. \[[@CR34]\]T2DM normal ABI^a^0.90------1.73.75.920.926.8--UKNAT2DM borderline ABI^b^0.88------3.87.812.022.629.1--UKNAT2DM PAD^c^0.80------14.021.933.623.236.4--UKNA Ji et al. \[[@CR35]\]T2DM normal BMI^d^0.90------9.66.315.626.716.6--UKSelf-administeredT2DM overweight BMI^e^0.85------14.28.121.439.723.8--UKSelf-administeredT2DM obese BMI^f^0.81------14.37.123.458.429.9--UKSelf-administered Zhu et al. \[[@CR36]\]Diabetes mellitus0.800.15----------------JapanFace-to-face Cao et al. \[[@CR37]\]Diabetes mellitus0.940.14----15.07.913.522.28.1JapanFace-to-faceHypertension Li et al. \[[@CR47]\]Hypertension0.800.17----------------UKFace-to-face He et al. \[[@CR48]\]Hypertension0.780.1977.414.4------------UKNA Wang \[[@CR49]\]Hypertension0.840.2270.119.015.44.89.945.216.8--UKFace-to-face Wang et al. \[[@CR50]\]Hypertension0.910.1571.014.68.03.16.626.113.1--JapanFace-to-face Zhu et al. \[[@CR36]\]Hypertension0.800.13----------------JapanFace-to-face Cao et al. \[[@CR37]\]Hypertension0.930.14----14.68.413.020.27.4--JapanFace-to-face Zhang et al. \[[@CR51]\]Hypertension0.920.17----6.83.66.511.35.8--ChinaFace-to-faceCoronary heart disease Cao et al. \[[@CR37]\]Coronary heart disease0.900.16----17.79.415.424.28.1JapanFace-to-face Xiong et al. \[[@CR38]\]Coronary heart disease0.860.1577.513.8------------JapanTelephone Wang et al. \[[@CR39]\]Coronary heart disease0.890.1771.617.717.99.515.524.37.9--JapanFace-to-face Wu et al. \[[@CR40]\]Chronic stable angina0.780.1571.212.415.813.4------15.6ChinaFace-to-face Wu et al. \[[@CR41]\]Chronic stable angina0.75--71.2--15.813.460.355.756.015.6UKFace-to-faceCOPD Zhu et al. \[[@CR36]\]COPD0.760.15----------------JapanFace-to-face Wu et al. \[[@CR42]\]COPD0.730.1566.616.239.117.337.838.029.4--JapanFace-to-face Chen et al. \[[@CR43]\]COPD0.640.3155.320.4----------22.1UKFace-to-face Ding et al. \[[@CR44]\]COPD0.800.30------------------Face-to-faceEpilepsy Gao et al. \[[@CR45]\]Epilepsy0.830.2179.616.47.67.615.334.747.9--UKFace-to-face Gao et al. \[[@CR46]\]Epilepsy0.870.2478.315.8------------UKFace-to-faceCerebral infarction He et al. \[[@CR52]\]Cerebral infarction0.53^j^--66.814.822.014.623.647.225.2--UKFace-to-face Wei \[[@CR53]\]Cerebral infarction DBP^g^0.750.0879.023.5------------JapanFace-to-faceCerebral infarction NDBP^h^0.620.1264.918.4------------JapanFace-to-faceCerebral infarction ADBP^i^0.510.1149.717.0------------JapanFace-to-faceStroke Zhu et al. \[[@CR36]\]Stroke0.510.33----------------JapanFace-to-face Cao et al. \[[@CR37]\]Stroke0.900.17----21.213.520.724.010.1--JapanFace-to-faceChronic liver disease Che et al. \[[@CR54]\]Compensated0.700.2058.214.9------------ThailandFace-to-face Yu et al. \[[@CR55]\]Compensated0.800.03----------------JapanSelf-administered Che et al. \[[@CR54]\]Decompensated0.600.3047.623.4------------ThailandFace-to-face Yu et al. \[[@CR55]\]Decompensated0.630.05----------------JapanSelf-administered Che et al. \[[@CR54]\]Liver failure0.000.2036.417.2------------ThailandFace-to-face Che et al. \[[@CR54]\]HCC0.600.3050.616.9------------ThailandFace-to-face Yu et al. \[[@CR55]\]HCC0.410.07----------------JapanSelf-administeredOther diseases Chen \[[@CR56]\]Lung cancer0.790.2573.613.924.512.826.647.330.9--UKFace-to-face Chen et al. \[[@CR57]\]Esophagus cancer0.840.2275.211.018.212.022.038.325.448.8UKNA Cui \[[@CR58]\]Cerebral palsy0.440.1227.39.187.894.394.358.472.1--JapanFace-to-face Gu \[[@CR59]\]Rheumatoid arthritis0.560.30----------------UKFace-to-face Jiang \[[@CR60]\]Sarcopenia0.78--78.8--21.47.19.550.019.1--UKFace-to-face Wang et al. \[[@CR61]\]Atrial fibrillation0.810.2570.314.427.537.322.912.521.6----Face-to-face Farooq et al. \[[@CR62]\]Kashin--beck disease0.450.3060.518.076.157.169.389.975.8--UKFace-to-face Zhao et al. \[[@CR63]\]Chronic prostatitis0.730.1569.214.23.00.06.382.169.4--UKFace-to-face Sun et al. \[[@CR64]\]Hemophilia0.710.2071.0^k^21.0^k^71.827.358.265.560.0--USAWeb-based Lin et al. \[[@CR65]\]Visual impairment0.85------23.610.420.143.739.3----Face-to-face*VAS* visual analogue scale, *SD* standard deviation, *T2DM* type 2 diabetes mellitus, *ABI* ankle-brachial index, *PAD* peripheral arterial disease, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *DBP* dipper blood pressure, *NDBP* non-dipper blood pressure, *ADBP* anti-dipper blood pressure, *HCC* hepatocellular cancer, *NA* not available, *HRQoL* health-related quality of life, *EQ-5D-3L* 3 level version of EuroQol 5-Dimensions, -- not reported in excluded study^a^Normal ABI: 1.00 \< ABI ≤ 1.40^b^Borderline ABI: 0.9 \< ABI ≤ 0.99^c^PAD: ABI ≤ 0.9.^d^Normal BMI: 18.5 ≤ BMI \< 24.0^e^Overweight BMI: 24.0 ≤ BMI \< 28.0^f^Obese BMI: 28.0 ≤ BMI^g^DBP 10%≤Nocturnal Reduction Rate ≤ 20%^h^NDBP: 10% \> Nocturnal Reduction Rate^i^ADBP: 20% \< Nocturnal Reduction Rate.^j^Only reported median utility value^k^The original data were scaled in 10-point system

Diabetes mellitus {#Sec7}
-----------------

In this review, ten studies reported health utilities for diabetes mellitus \[[@CR28]--[@CR37]\]. The extreme values as well as the utility values that ranged from 0.79 to 0.94 were calculated by Japanese value set. However, the study with the highest values \[[@CR37]\] was conducted in rural communities and reported a younger mean age (57.2 vs. 63.2 years) without any comorbidity compared to the study that was conducted at a hospital and that described a few serious T2DM comorbidities (hyperlipidemia, cardiovascular disease, and hypertension) with the lowest value \[[@CR30]\]. Interestingly, when applied in Chinese value set, the results from Tang's study that included about 415 T2DM patients was 0.84 \[[@CR31]\]. The EQ-5D VAS scores were from 61.5 to 78.6 in four studies \[[@CR28], [@CR29], [@CR31], [@CR32]\]. The decrease of health utility in DM patients was mainly caused by problems related to "Pain/Discomfort" and "Anxiety/Depression" dimensions. Hypertension, hyperlipemia, and CHD were the most common DM comorbidities reported by the studies, and the prevalence of DM comorbidities was from 42.6 to 81.5%, thus having a significant influence on HRQoL.

Hypertension {#Sec8}
------------

For the patients with hypertension, the utility values ranged from 0.78 to 0.93 in six studies \[[@CR36], [@CR37], [@CR47]--[@CR51]\]. Japanese value set and UK value set were applied in the hypertension disease population in the studies that reported the highest value \[[@CR37]\] and the lowest value \[[@CR48]\], respectively. We found that the study \[[@CR37]\] with the highest value reported a younger mean age without any comorbidity compared to the study \[[@CR48]\] on patients with hypertension and comorbidities. The EQ-5D VAS scores were from 70.1 to 77.4 in three studies \[[@CR48]--[@CR50]\]. "Pain/Discomfort" was the dimension with the most problems reported by the patients in three studies \[[@CR37], [@CR49], [@CR50]\].

Coronary heart disease {#Sec9}
----------------------

For the patients with CHD, the utility values ranged from 0.75 to 0.90 in five studies \[[@CR37]--[@CR41]\]. Two of them were about chronic stable angina (CSA) patients, which was a subgroup of CHD \[[@CR40], [@CR41]\]. The extreme values were generated by UK \[[@CR41]\] (0.75) and Japanese value set \[[@CR37]\] (0.90), respectively. In general, the mean age of CHD patients with highest utility was 57.2 years old and 68.1 years for those with the lowest utility. Moreover, the former was concerned with CHD patients without comorbidity in rural areas \[[@CR41]\], while the latter included more serious CSA patients with comorbidities at hospitals \[[@CR36]\]. Chinese and UK values have been separately applied in the same CHD sample in a previous study by Wu et al. \[[@CR30], [@CR41]\], and health utility calculated by Chinese value set \[[@CR40]\] (0.78) was a little bit higher compared to UK set \[[@CR41]\] (0.75). In terms of EQ-5D VAS scores, they ranged from 71.2 to 77.5 in four studies \[[@CR38]--[@CR41]\]. "Pain/Discomfort" was the dimension with the most problems reported by CHD patients in two studies \[[@CR36], [@CR38]\], while "Usual Activities" in CSA patients \[[@CR40], [@CR41]\]. Prevalence of comorbid hypertension most commonly occurred among CHD patients, followed by DM \[[@CR37]\].

Chronic obstructive pneumonia disease {#Sec10}
-------------------------------------

The health utility values for COPD patients ranged from 0.64 to 0.80 in four studies \[[@CR36], [@CR42]--[@CR44]\]. The lowest value was calculated by UK value set \[[@CR43]\]; however, the study that reported highest value did not describe the value set applied \[[@CR44]\]. Patients with the highest value had a younger mean age and better post-bronchodilator FEV~1~ of predicted than the lowest one. Two studies reported that EQ-5D VAS scores were 55.3 \[[@CR43]\] and 66.6 \[[@CR42]\], respectively. The decrease of health utility in COPD patients was mainly caused by problems in "Mobility" dimension that were only described in one study \[[@CR42]\]. The prevalence of comorbidities in COPD patients was from 67.5 to 78.9% \[[@CR42], [@CR43]\].

Epilepsy {#Sec11}
--------

The health utility values for epilepsy patients ranged from 0.83 to 0.87 in two studies \[[@CR45], [@CR46]\], and both were calculated by UK value set. The patients in the study \[[@CR46]\] that reported a higher utility were a little bit younger compared to patients in another study \[[@CR45]\]. Besides that, it is possible that disease duration negatively affects the utility, since mean epilepsy duration of 8.5 years was reported in the study with lower value \[[@CR45]\] compared to 6.0 years reported by another study \[[@CR45]\]. EQ-5D VAS scores were 78.3 \[[@CR46]\] and 79.6 \[[@CR45]\], respectively. "Anxiety/Depression" was the most problematic dimension followed by "Pain/Discomfort" \[[@CR45]\].

Cerebral infarction {#Sec12}
-------------------

In terms of health utility for patients with CI, two studies reported the HRQoL \[[@CR52], [@CR53]\]. Among these, one included three subgroup analyses based on different types of blood pressure \[[@CR53]\]. The utility values and VAS scores were much lower in anti-dipper blood pressure group (0.51/49.7) compared to dipper blood pressure group (0.75/79.0). The decrease of health utility in CI patients was mainly caused by problems in "Mobility" dimension \[[@CR52]\].

Stroke {#Sec13}
------

For the patients with stroke, the health utility ranged from 0.51 to 0.90 in two studies evaluated by Japanese value set \[[@CR36], [@CR37]\]. The wide range of utility values for stroke was caused by the variation in mean age, comorbidities, and disease severity, etc. "Pain/Discomfort" was the dimension with most problems followed by "Mobility" \[[@CR37]\]. No information was available on EQ-5D VAS score.

Chronic liver disease {#Sec14}
---------------------

The health utility values for patients with CLD differed in disease severity. The values ranged from 0.70 to 0.80 for compensated patients \[[@CR54], [@CR55]\], while it ranged from 0.60 to 0.63 for decompensated patients \[[@CR54], [@CR55]\]. When the disease deteriorated to HCC, utility values were from 0.41 to 0.60 \[[@CR54], [@CR55]\], which was lower compared to compensated or decompensated patients. In addition, the health utilities of liver failure were 0.00 \[[@CR54]\] which was equal to death. In terms of EQ-5D VAS scores, they ranged from 36.4 \[[@CR54]\] (for liver failure) to 58.2 \[[@CR54]\] (for compensated) in the study. There were no results on the most problematic dimension in CLD patients.

Other diseases {#Sec15}
--------------

For the remaining ten diseases \[[@CR56]--[@CR65]\], i.e., lung cancer, sarcopenia, and hemophilia, the health utility value for each disease was only reported by one study.

Among the ten diseases, cerebral palsy was 0.44 \[[@CR58]\] for the utility value which was the lowest one, while the highest one was 0.85 \[[@CR64]\] in visually impaired patients. Japanese value set was applied in cerebral palsy patients. In terms of EQ-5D VAS scores, they ranged from 27.3 \[[@CR58]\] (cerebral palsy) to 78.8 \[[@CR60]\] (sarcopenia). "Pain/Discomfort" or "Anxiety/Depression" was the dimensions that caused most problems according to majority of studies.

Discussion {#Sec16}
==========

The present review focused on HRQoL in chronic non-communicable diseases in Chinese population. Over recent years, EQ-5D-3L questionnaire has been increasingly applied in different patient groups in China to measure their health utility values. Among 18 different types of diseases, DM, CHD, COPD, and hypertension are the most common CNCDs in China. Due to the high morbidity and mortality rates from these CNCDs, people have become more than ever concerned about the patients' state of survival and HRQoL.

Patient-reported outcomes are important to health decision-makers. As a generic instrument, EQ-5D can be easily used by patients to report their HRQoL. However, there are variations in health utility values for a specific CNCD among different studies. Given the level of heterogeneity is high regarding patient characteristics and study design, meta-analysis is not an appropriate method to calculate a single index across studies. The utility values of DM (0.79--0.94), CHD (0.75--0.90), COPD (0.64--0.80), hypertension (0.78--0.93), epilepsy (0.83--0.87), CI (0.51--0.75), stroke (0.51--0.90), and CLD (0.00--0.80) reflect HRQoL in patients with CNCDs and with different conditions in a QALY framework. The results can be changed by a series of factors, including age, gender, sample source, comorbidities, rural/urban, and value set. In general, the health status deteriorates as people get old. Thus, the utility value decreases with the increasing age. According to previous study, the values in patients with T2DM aged 60 and over (0.83) was lower compared to patients with T2DM who were younger than 60 (0.86) \[[@CR23]\].

In most of the studies that reported on gender-specific health utility values and were included in the present review \[[@CR28]--[@CR30], [@CR38], [@CR39], [@CR48], [@CR49], [@CR56], [@CR57]\] men had a better HRQoL compared to women, e.g., with reference to lung cancer, man had 0.81, whereas woman had 0.76 value \[[@CR56]\]. These results are in line with what has observed in the general population that men have a higher mean EQ-5D value score than women \[[@CR23], [@CR66]\]. Besides gender, community-based or hospital-based cross-sectional surveys also have influence on the HRQoL assessment. It is logical to expect that patients in hospital will report more problems compared to stay at home patients. In line with previous statement, Chen et al. \[[@CR43]\] conducted a survey to measure health utility in patients with COPD at hospital, while Zhu et al. \[[@CR36]\] conducted the same survey in community, and the values have shown to lower in the former sample.

Comorbidity has an important role in the variation of health utility value. In addition to the number of comorbidities, different types of comorbidities can affect health utility values as well. Hypertension, DM, CHD, hyperlipidemia, and stroke are the most common comorbid conditions \[[@CR28], [@CR30], [@CR36]--[@CR38]\] The HRQoL in patients who do not have comorbidities with other diseases is better compared to the patients with comorbidities. Luo has reported that the value of utility in people only suffering DM was 0.86; however, it dropped to 0.69 when there were other comorbid conditions present \[[@CR30]\]. Thus, the value of utility decreases in the presence of other comorbid diseases. In Liang's study \[[@CR29]\], DM patients with one, two, or more than two kinds of comorbidities revealed the utility value of 0.86, 0.83, and 0.81, respectively. Moreover, various comorbidities have different interaction effects on health utility. When patients have different kinds of comorbid conditions, HRQoL may change. According to Wang, patients with CHD and hypertension, and DM or stroke have the utility values of 0.89, 0.87, and 0.85, respectively. Stroke is a serious comorbidity in many diseases \[[@CR32], [@CR37], [@CR39], [@CR67]\].

China is a country with dual economic structure between rural and urban areas \[[@CR68]\] Due to the special economic structure, social policy and welfare are different for citizens living in city and countryside, and thus the medical service system and social insurance may have an impact on HRQoL. With reference to the impact of urban/rural context on HRQoL, it is still a matter of some controversy. Chen has reported that EC patients living in rural areas have a higher health utility value compared to those living in urban areas \[[@CR57]\]. However, as regards to people with LC, there has been no difference between rural and urban areas \[[@CR56]\]. In China, most rural people are covered by "New Rural Cooperative Medical Insurance (NRCMI)," while urban people are covered by "Urban Residents Basic Medical Insurance (URBMI)" and "Urban Employee Basic Medical Insurance (UEBMI)." By the end of 2015, there were approximately 670 million, 377 million, 289 million people enrolled in NRCMI, URBMI, and UEBMI, respectively \[[@CR69]\]. However, medical resources are distributed unequally, most of which are allocated in tertiary hospitals in urban areas. Furthermore, larger gap exists in terms of quality of medical services between urban and rural areas. Su et al. \[[@CR70]\] compared the effects of NRCMI, URBMI, and UEBMI on HRQoL, and the results showed that the insured people of UEBMI had a higher mean EQ-5D utility score. Besides that, the horizontal inequality index suggested that there existed a higher pro-rich health inequity in NRCMI than urban schemes.

The application of value sets from various countries in the same disease population leads to different results in health utility values. In the same sample of patients with CHD \[[@CR40]\], the values reported by Chinese value set were higher compared to UK value set \[[@CR41]\]. The estimations of EQ-5D-3L value sets are based on local people's health preference and are affected by culture, social environment, and economic development. Furthermore, the preference in health might vary across different countries. Time trade-off is the most widely accepted method for estimating a EQ-5D-3L value set. Respondents are asked to imagine a certain health condition described by EQ-5D-3L that would be experienced for a fixed time (e.g., 10 years) and then to compare it with a shorter time in full health. Five countries' value sets (Japan \[[@CR71]\], China \[[@CR72]\], UK \[[@CR73]\], Thailand \[[@CR74]\], USA \[[@CR75]\]) applied in the included studies are showed in Appendix Table [5](#Tab5){ref-type="table"}. The best ill health state value is 0.961 with Chinese value set, higher than other four countries', which indicates the departure from full health declines less in health state value. "Pain/Discomfort" and "Anxiety/Depression" dimensions have a larger impact on disutility when applied in UK and USA value sets, while "Usual Activities" in Chinese value set. Chinese EQ-5D-3L value set has been estimated in 2014 \[[@CR72]\], and it has shown to be the most appropriate set to use for exploration of the HRQoL in disease or general population in China.

EQ-5D-3L may lead to ceiling effects when measure HRQoL and health decrements may not be sensitive in disease population \[[@CR76]\]. Five-level version (EQ-5D-5L) was introduced by EuroQol Group in 2005 \[[@CR77]\] to reduce ceiling effects and improve the questionnaire's sensitivity to mild changes in health that cannot be capture by EQ-5D-3L. Both the EQ-5D-3L and EQ-5D-5L comprise the same five dimensions, but EQ-5D-5L is added two more levels in each dimension: "have no problems/be not," "have slight problems/be slightly," "have some/moderate problems," "have severe problems/be severely," "have extremely problems/unable to." Therefore, EQ-5D-5L can define 3125 kinds of different health states. Although new version of EQ-5D questionnaire has some advantages over old version, EQ-5D-5L value sets have only been published since 2016. Chinese EQ-5D-5L value set has recently been estimated in 2017 \[[@CR78]\]. The broad application of EQ-5D-5L country-specific value sets are limited by the publication time. Most of researchers are unfamiliar with the new value sets. In view of this, when conducting a health economic assessment or population survey, researchers are still accustomed to using EQ-5D-3L to measure health utilities.

Compared with other countries' patients, the health utility of European people with T2DM was 0.69 and it was 0.65 in New Zealand and Australia \[[@CR79], [@CR80]\]. In general, the HRQoL of Chinese T2DM patients might be better than these countries' T2DM sufferers. A systematic review reported that the utility values of cardiovascular disease patients ranged from 0.24 to 0.90 \[[@CR81]\], and the highest EQ-5D-3L values were reported in people living with CHD. For COPD patients, a meta-analysis reported the utility values were from 0.62 to 0.82 by severity of the disease \[[@CR82]\], and the results were similar to COPD patients in China.

The main limitation of this review is number of studies reporting on each CNCD. Even though 18 different kinds of diseases were included, more than half of the CNCDs were reported separately. Due to the lack of sufficient information on health utility for some of the CNCDs discussed above, it is difficult to get accurate conclusions about the HRQoL in various Chinese population with CNCDs.

The comparison and analysis of HRQoL across different populations with CNCDs is of utmost importance. Utility value is a single index that reflects synthetic information about people's health, and that can provide useful evidence for decision-makers upon optimizing the allocation of health resources.

Appendix {#Sec17}
========

See Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}.

Table 3Literature search strategiesSearch termsDatabasesPubMedEmbaseWeb of scienceCochrane library\#1Quality of life218,659385,677388,56275,309\#2QoL30,55156,70228,49910,349\#3HRQoL12,77420,08412,3503340\#4\#1 or \#2 or \#3220,618392,362390,23476,062\#5eq-5d582510,98862593390\#6EuroQol4051605742982277\#7Five dimension154505826,161628\#8\#5 or \#6 or \#7775418,37533,7954533\#9\#4 and \#8569111,10776163698\#10China128,958153,634488,51140,413\#11Chinese170,044221,032326,13549,739\#12\#10 or \#11267,060335,522733,45671,681\#13\#9 and \#12140273220284\#14\#4 and \#124284730289805892\#15\#8 and \#121954441023302\#16\#14 or \#154339747397835903\#17RCT16,67227,77116,305512,063\#18Randomized controlled trial53,410295,111387,155628,242\#19Clinical trial118,324326,333582,836688,438\#20\#17 or \#18 or \#19177,958502,861806,195983,165\#21\#14 not \#20388763137325491\#22\#15 not \#201834189809\#23\#13 not \#2013625719410\#24\#21 or \# 22393764748111491\#25Disease2,696,7473,686,9793,592,538266,098\#26Chronic non-communicable5667291390136\#27\#25 or \#262,697,0283,687,3553,592,546266,115\#28\#16 and \#271189217724893537\#29\#24 and \#27108318731871200

Table 4AHRQ checklist scoring1234567891011ScoresZhu \[[@CR28]\]YYYUCNYYYYYUC8Liang \[[@CR29]\]YYYUCNYNYNNUC5Luo et al. \[[@CR30]\]YYYYNYNYNNUC6Tang et al. \[[@CR31]\]YYYUCNYNYNNUC5Han et al. \[[@CR32]\]YYYYYYNYNYUC8Chang \[[@CR33]\]YYYNYNYYNYUC7Yan et al. \[[@CR34]\]YYYUCYNYYNYUC7Ji et al. \[[@CR35]\]YYYUCNYYNYNUC6Zhu et al. \[[@CR36]\]YYNUCNYNYNNUC4Cao et al. \[[@CR37]\]YYYUCNYNYNNUC5Xiong et al. \[[@CR38]\]YYYYNYNYYNY8Wang et al. \[[@CR39]\]YYYUCYYNYNYUC7Wu et al. \[[@CR40]\]YYYUCYYNYNYUC7Wu et al. \[[@CR41]\]YYYUCNYYYNYUC7Wu et al. \[[@CR42]\]YYYYNYNYNYUC7Chen et al. \[[@CR43]\]YYYYNYYYNYUC8Ding et al. \[[@CR44]\]YYYYYYNYNYUC8Gao et al. \[[@CR45]\]YYYUCYYNYNNUC6Gao et al. \[[@CR46]\]YYYUCNYNYNNUC5Li et al. \[[@CR47]\]YYYUCNYNYNYUC6He et al. \[[@CR48]\]YNYUCNYNNNYUC4Wang \[[@CR49]\]YYYYYYNYNNUC7Wang et al. \[[@CR50]\]YYYUCNYNYNNUC5Zhang et al. \[[@CR51]\]YYYYNYNYNYUC7He et al. \[[@CR52]\]YYNUCYYNNNNUC4Wei \[[@CR53]\]YYYYYYYYNYY10Che et al. \[[@CR54]\]YYYYNYNYNNUC6Yu et al. \[[@CR55]\]YYYYNYNYNNUC6Chen \[[@CR56]\]YYYYYYNYNYUC8Chen et al. \[[@CR57]\]YYYYNYNYNYUC7Cui \[[@CR58]\]YYYUCNYNYNYUC6Gu \[[@CR59]\]YYYYYYNYNNUC7Jiang \[[@CR60]\]YYYYYYYYNYUC9Wang et al. \[[@CR61]\]YYYYYNYNNNUC7Farooq et al. \[[@CR62]\]YYYUCNYNNNYUC6Zhao et al. \[[@CR63]\]YYYYYYYYNYUC9Lin et al. \[[@CR64]\]YYYYNYNYNNY7Sun et al. \[[@CR65]\]YYYUCYYNYNNUC6*Y* yes, *UC* unclear, *N* no, *AHRQ* agency for health research and quality. *AHRQ checklist items* 1---Define the source of information, 2---List inclusion and exclusion criteria for exposed and unexposed subjects or refer to previous publications. 3---Indicate time period used for identifying patients. 4---Indicate whether or not subjects were consecutive if not population-based. 5---Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants. 6---Describe any assessments undertaken for quality assurance purposes. 7---Explain any patient exclusions from analysis. 8---Describe how confounding was assessed and/or controlled. 9---If applicable, explain how missing data were handled in the analysis. 10---Summarize patient response rates and completeness of data collection. 11---Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained

Table 5The EQ-5D-3L value sets of five countriesJapan \[[@CR71]\]China \[[@CR72]\]UK \[[@CR73]\]Thailand \[[@CR74]\]USA \[[@CR75]\]Constant0.1520.0390.0810.202--MO20.0750.0990.0690.1210.146MO30.4180.2460.3140.4320.558SC20.0540.1050.1040.1210.175SC30.1020.2080.2140.2420.471UA20.0440.0740.0360.0590.140UA30.1330.1930.0940.1180.374PD20.0800.0920.1230.0720.173PD30.1940.2360.3860.2090.537AD20.0630.0860.0710.0320.156AD30.1120.2050.2360.1100.450N3--0.0220.2690.139--D1--------− 0.140(I2)\^2--------0.011(I3)--------− 0.122(I3)\^2--------− 0.015Sample size6211147339514094048States directly valued1797428642Valuation methodTTOTTOTTOTTOTTORange(− 0.111, 0.804)(− 0.149, 0.961)(− 0.594, 0.883)(− 0.452, 0.766)(− 0.102, 0.860)*mo* mobility, *SC* self-care, *UA* usual activities, *PD* pain/discomfort, *AD* anxiety/depression, *N3* any dimension is at level 3, *D1* the number of dimension not at level 1, minus 1, *I2* the number of dimension is level 2, minus 1, *(I2)\^2* the square of I2, *I3* the number of dimensions at level 3, minus 1, *(I3)\^2* the square of I3, *TTO* time trade-off
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